MedTrace Logo

Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus

NCT06632561 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-10-09

No results posted yet for this study

Summary

The study is a short to mid-term randomized single-blind placebo controlled study that aimed to detect the effects of empagliflozin (a sodium-glucose cotransporter-2 inhibitor) compared to placebo on LV end-diastolic and end-systolic volumes, LV ejection fraction, N-terminal pro-B-type natriuretic peptide (NT-proBNP), functional capacity and quality of life (QoL) among non-diabetic patients with HFrEF.

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Empagliflozin 10 mg

Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months

DRUG

Placebo

Sugar pills one tablet daily for 6 months

Sponsors & Collaborators

  • Ashraf Wasfy Beshay Aziz

    lead OTHER

Principal Investigators

  • Hesham B Mahmoud, Professor of Cardiology · Beni-Suef University

  • Mohammad Sh Awad, Assistant Professor Cardiology · Beni-Suef University

  • Mohammed M Tohamy, Lecturer of Cardiology · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2022-03-09
Completion
2022-03-14

Countries

  • Egypt

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06632561 on ClinicalTrials.gov